Gastrointestinal Cancer

The Pharmacy Times® Gastrointestinal Cancer Resource Center is a comprehensive resource for clinical news and expert insights on cancers that occur in digestive tract organs, such as the stomach, large and small intestine, pancreas, colon, liver, rectum, anus, and biliary system.

Latest News

Primary biliary cholangitis written on post-it note -- Image credit: syahrir | stock.adobe.com
FDA Grants Orphan Drug Designation to CNP-104 for Primary Biliary Cholangitis

January 10th 2025

The designation follows positive phase 2a trial results (NCT05104853) presented at the 2024 AASLD The Liver Meeting.

FDA Approval, Oncology, Gastric Cancer | Image Credit: © wladimir1804 | stock.adobe.com
FDA Approves Tislelizumab in Combination With Chemotherapy for Gastric, Gastrosophageal Junction Adenocarcinoma

January 2nd 2025

Magnifying glass showing FDA logo -- Image credit: Ihar | stock.adobe.com
FDA Reports Serious Liver Injury in Patients Without Cirrhosis Using Obeticholic Acid to Treat PBC

December 12th 2024

Laptop displaying FDA logo -- Image credit: monticellllo | stock.adobe.com
FDA Grants PLT012 Orphan Drug Designation for Liver, Intrahepatic Bile Duct Cancer

December 11th 2024

Lung cancer concept | Image Credit: © Mikki Orso - stock.adobe.com
Zenocutuzumab-zbco Granted Accelerated Approval for Patients With NSCLC, Pancreatic Ductal Adenocarcinoma

December 5th 2024

Latest CME Events & Activities

The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...

2.0 Credits / Human Trafficking, Law

View More

Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies

1.0 Credit / Law, Pain Management, Opioids

View More

More News

FDA OKs Biosimilar Treatment for Certain Breast and Stomach Cancers

FDA OKs Biosimilar Treatment for Certain Breast and Stomach Cancers

December 1st 2017

The FDA has approved trastuzumab-dkst (Ogivri, Mylan GmbH) as a biosimilar to trastuzumab (Herceptin, Genentech), the first biosimilar for the treatment of certain breast and stomach cancers.

Read More

<123